Abstract

Objectives: The current research aimed to evaluate the role of fine needle aspiration biopsy (FNAB) and CD3, CD20 and CD45 in the identification of oral primary diffuse large B-cell lymphoma (DLBCL). Materials and methods: This is a descriptive clinical study. Ten patients clinically diagnosed as DLBCL in a tertiary level hospital in Qassim, Saudi Arabia; were included. Fine needle aspiration and incisional biopsies were taken from each patient and processed in the appropriate manner. Histopathological confirmation was done using haematoxylin and eosin stained specimens. Other sections were taken for the immune histochemistry using a standard strept-avidin-biotin peroxidase procedure and monoclonal antibodies, including CD3, CD20 and CD45. Results: The obtained results showed positivity of FNAB in 7 cases and three cases were inconclusive. Strong positive immune reaction was revealed with CD20 and CD45, while CD3 was negative in all studied cases. Conclusion: These findings indicated the diagnostic significance of FNAB, CD20 CD45 and CD3 in proper diagnosis of oral DLBCL. More research is necessary for predicting the prognostic importance of these molecular markers in oral lymphomas.

Keywords: B-cell lymphoma · CD3 · CD20 · CD45 · FNAB

References

  1. 1.Mahima VG, Patil K, RainaA. Extra nodal non-hodgkin’s lymphoma. An unfamiliar presentation in the oral cavity: A case report. Int J Clin Cases Invest. 2010:1–6.
  2. 2.Razmpa E, Saedi B. Clinical features of extra nodal presentation of non-hodgkin’s lymphoma in head and neck. Acta Medica Iranica. 2009;47:489–92.
  3. 3.Vega f, Lin p, Medeiros LJ. Extranodal lymphomas of the head and neck.Ann Diagn Pathol. 2005;9(6):340-50.
  4. 4.J. S. Lee, P. M. Bracci, and E. A. Holly, “Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use,” American Journal of Epidemiology, vol. 168, no. 3, pp. 278–288, 2008.
  5. 5.A. M. Evens, R. Advani, I. S. Lossos, et al., “Lymphoma in pregnancy: excellent fetal outcomes and maternal survival in a large multicenter analysis,” Blood, vol. 118,Abstract 94, 2011.
  6. 6.Adwani DG, Arora Rajender Singh RS, BhattacharyaAnirudhA, Bhagat Bhushan B. Non-Hodgkin’s lymphoma of maxillary sinus: An unusual presentation. Ann Maxillofac Surg. 2013;3(1):95–7.
  7. 7.Epstein JB, Epstein JD, Nhu D Le, Gorsky M. Characteristics of oral and paraoral malignant lymphoma: A population- 17 17 Majmaah Journal of Health Sciences ,Vol. 6, Issue 2, September 2018, Muharam - 1440 Application of Fine NeedleAspiration Biopsy and Immunohistochemical Diagnostic Markers in the Identification of Oral Primary... based review of 361 cases. Oral Surg Oral Med Oral Pathol Oral Radil Endod. 2001;92:519–25.
  8. 8.Abadi RZM, Sistani NS, Mohtasham N, Hesari KK, Vaezi T, Pazouki M, et al. The prevalence of Epstein-Barr virus infection in head and neck non-Hodgkin’s lymphomas in Khorasan, northeast of Iran. J Pak MedAssoc. 2013;63:882–87.
  9. 9.Pileri SA, Dirnhofer S, Went P, Ascani S, Sabattini E, Marafioti T, et al. Diffuse large B-cell lymphoma: One or more entities? Present controversies and possible tools for its sub classification. Histopathology.2002;41:482–509.
  10. 10.Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. Lyon: IARC Press; 2001. World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues.
  11. 11.Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol. 2001;13:325–34.
  12. 12.Kolokotronis A, Konstantinou N, Christakis I, Papadimitriou P, Matiakis A, Zaraboukas T, et al. Localized B-cell non-Hodgkin’s lymphoma of oral cavity and maxillofacial region: A clinical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:303–10.
  13. 13.Coiffier B. State-of-the-art therapeutics: Diffuse large B-cell lymphoma. J Clin Oncol. 2005;23:6387–93.
  14. 14.Eisenbud L, Sciubba J, Mir R, Sachs SA. Oral presentations in non-Hodgkin’s lymphoma: a review of thirty-one cases. Part II. Fourteen cases arising in bone. Oral Surg Oral Med Oral Pathol. 1984;57:272–
  15. 15.Singh S, Garg N, Gupta S, et al. Fine needle aspiration cytology in lesions of oral and maxillofacial region: Diagnostic pitfalls. Journal of Cytology / Indian Academy of Cytologists. 2011;28(3):93-97. doi:10.4103/0970-9371.83461. doi:10.4103/0970-9371.83461
  16. 16.Dey P, KarmakarT. Fine needle aspiration cytology of accessory axillary breasts and their lesions.Acta Cytol 1994;38:915-6.
  17. 17.Cramer H, Lampe H, Downing P. Intraoral and transoral fine needle aspiration. A review of 25 cases. Acta Cytol. 1995;39:683–8.
  18. 18.Singhal N, Khurana U, Handa U, et al. Intraoral and Oropharyngeal Lesions: Role of Fine Needle Aspiration Cytology in the Diagnosis. Indian Journal of Otolaryngology and Head & Neck Surgery. 2015;67(4):381-387. doi:10.1007/ s12070-015-0875-y.
  19. 19.Castelli M, Gattuso P, Reyes C, Solans EP. Fine needle aspiration biopsy of intraoral and pharyngeal lesions. Acta Cytol. 1993;37:448–50.
  20. 20.Lilliemark J, Tani E, Mellstedt H, Skoog L. Fine-needle aspiration cytology and immunocytochemistry of malignant non-Hodgkin’s lymphoma in the oral cavity. Oral Surg Oral Med Oral Pathol. 1989;68:599–603.
  21. 21.Orell SR, Sterret GF, Whitaker D, Klijanienko J. Head and Neck; salivary glands. In: Orell SR, Sterett GF, Whitaker D, edi- Majmaah Journal of Health Sciences ,Vol. 6, Issue 2, September 2018, Muharam - 1440 18 18 Application of Fine NeedleAspiration Biopsy and Immunohistochemical Diagnostic Markers in the Identification of Oral Primary... tors. Fine needle aspiration cytology. 4th ed. USA: Churchill Livingstone; 2005. pp. 41–77.
  22. 22.Lee SS, Cho KJ, Jang JJ, Ham EK. Differential diagnosis of adenoid cystic carcinoma from pleomorphic adenoma of the salivary gland on fine needle aspiration cytology. Acta Cytol.1996;40:1246–52.
  23. 23.Ustundag E, Iseri M, Aydin O, Dal H, Almac A, Paksoy N. A denoid cystic carcinoma of tongue. J Laryngol Otol. 2000;114:477–80.
  24. 24.Sahai K, Kapila K, Dahiya S, Verma K. Fine needle aspiration cytology of minor salivary gland tumors of the palate. Cytopathology. 2002;13:309–16.
  25. 25.Wantanabe K, Ono N, Saito K, Saito A, Suzuki T. Fine-needle aspiration cytology of polymorphous low-grade adenocarcinoma of the tongue. Diagn Cytopathol. 1999;20:167–9.
  26. 26.Patil R, Nayak S, Munshi M, Bobhate S. Scrape cytology in rare case of hairy tongue. J Cytol.2009;26:91–3.
  27. 27.Mehdi G, Ansari HA, Haider N. Cytological diagnosis of multiple myeloma presenting as a jaw swelling. J Cytol. 2009;26:80–2.
  28. 28.Ramzy I, Aufdemorte TB, Duncan DL. Diagnosis of radiolucent lesions of jaw by fine needle aspiration biopsy. Acta Cytol. 1985;29:419–24.
  29. 29.Deshpande A, Umap P, Munshi M. Granular cell ameloblastoma of the jaw. A report of two cases with fine needle aspiration cytology. Acta Cytol. 2000;44:81–5.
  30. 30.Bhattacharyya I, Chehal HK, Cohen DM, Al-Quran SZ. Primary diffuse large B- Cell lymphoma of the oral cavity: Germinal center classification. Head Neck Pathol. 2010;4:181–91.
  31. 31.Holst J, et al. Scalable signaling mediated by T cell antigen receptor-CD3 ITAMs ensures effective negative selection and prevents autoimmunity. Nat Immunol. 2008;9:658–666.
  32. 32.Krogsgaard M, Davis MM. How T cells ‘see’ antigen. Nat Immunol. 2005;6:239–
  33. 33.Call ME, Wucherpfennig KW. Common themes in the assembly and architecture of activating immune receptors. Nat Rev Immunol. 2007;7:841–850.
  34. 34.Weiss A. T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases. Cell. 1993;73:209–212.
  35. 35.Hedrick SM, Cohen DI, Nielsen EA, Davis MM. Isolation of cDNAclones encoding T cell-specific membrane-associated proteins. Nature. 1984;308:149–153.
  36. 36.MalissenM,etal.MouseTcellantigenreceptor: structure and organization of constant and joining gene segments encoding thebetapolypeptide. Cell. 1984;37:1101– 1110.
  37. 37.YanagiY,YoshikaiY,LeggettK,ClarkSP, Aleksander I, Mak TW. A human T cellspecific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature. 1984;308:145–
  38. 38.19 19 Majmaah Journal of Health Sciences ,Vol. 6, Issue 2, September 2018, Muharam - 1440 Application of Fine NeedleAspiration Biopsy and Immunohistochemical Diagnostic Markers in the Identification of Oral Primary...
  39. 39.Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol. 2004;41:599–613.
  40. 40.Kadlecek TA, et al. Differential requirements for ZAP-70 in TCR signaling and T cell development. J Immunol. 1998;161:4688–4694.
  41. 41.Letourneur F, Klausner RD.Activation of T cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon. Science. 1992;255:79–82.
  42. 42.Combadiere B, Freedman M, Chen L, Shores EW, Love P, Lenardo MJ. Qualitative and quantitative contributions of the T cell receptor zeta chain to mature T cell apoptosis. J Exp Med. 1996;183:2109– 2217.
  43. 43.Love PE, Shores EW. ITAM multiplicity and thymocyte selection: how low can you go? Immunity.2000;12:591–597.
  44. 44.Pitcher LA, van Oers NS. T-cell receptor signal transmission: who gives an ITAM? Trends Immunol.2003;24:554–560.
  45. 45.Smith-Garvin JE, Koretzky G, Jordan MS. T cell activation. Annu RevImmunol. 2009;27:591–619.
  46. 46.Meeker T, Lowder J, Cleary ML. Emergence of idiotype variants during treatment of B-cell lymphoma with antiidiotype antibodies. N Engl J Med. 1985;312:1658-1665.
  47. 47.Maloney DG, Brown S, Czerwinski DK. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood. 1992;80:1502-1510.
  48. 48.Colombat P, Salles G, Brousse N. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101-106.
  49. 49.Hainsworth JD. Rituximab as firstline systemic therapy for patients with low-grade lymphoma. Semin Oncol. 2000;27:25-29.
  50. 50.Byrd JC, Murphy T, Howard RS. Rituximab using a three weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrated clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153- 2164.
  51. 51.Heras A, Roach CM, Key ME. Enhanced polymer detection system for immunohistochemistry. Lab Invest 1995;72:165.
  52. 52.Billroth T: Multiple Lymphome: Erfolgreiche Behandlung mit Arsenik. Wien Med Wochenschr 21:1066, 1871.
  53. 53.Virchow R: Die Cellularpathologie in ihrer Begrundung auf Physiologische und Pathologische Gewebelehr. Hirschwald, Berlin, 1858.
  54. 54.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. 4th ed. Lyon: IARC Press; 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Majmaah Journal of Health Sciences ,Vol. 6, Issue 2, September 2018, Muharam - 1440 20 20 Application of Fine NeedleAspiration Biopsy and Immunohistochemical Diagnostic Markers in the Identification of Oral Primary...
  55. 55.Muzaffar S, et al. Immunophenotypic analysis of non-Hodgkin’s lymphoma. JPMA J Pak Med Assoc. 1997 Apr; 47(4):106-9.
  56. 56.Shi Zonggao, Stack M Sharon. An Update on Immunohistochemistry in Translational Cancer Research. Year : 2015; 1(4):115-122
  57. 57.Kurtin PJ, Pinkus GS. Leukocyte common antigen-a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections using monoclonal antibodies: correlation with immunologic studies and ultrastructural localization. Hum Pathol. 1985 Apr; 16(4):353-65.
  58. 58.Center for Disease Control Manual. Guide: Safety Management, NO. CDC- 22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to RemoveAzide Salts.”
  59. 59.Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA2014.
  60. 60.National Committee for Clinical Laboratory Standards(NCCLS). Protection of laboratory workers from infectious diseasestransmittedbybloodandtissue;proposed guideline. Villanova, PA1991;7(9). Order code M29-P.
  61. 61.Zeeneldin AA, Sallam YA, Gaber AA, Shaheen AA. Non-anthracycline chemotherapy associated with a poor outcome in elderly Egyptian patients with diffuse large B-cell non-Hodgkin lymphoma. J Cancer Metastasis Treat 2015;1:76-83
  62. 62.Sanchez-Beato M, Sanchez-Aguilera A, PirisMA.CellcyclederegulationinB-cell lymphomas. Blood.2003;101:1220–35.
  63. 63.Pileri SA, Leoncini L, Falini B. Revised European-American Lymphoma Classification. Curr Opin Oncol. 1995 Sep;7(5):401-7.
  64. 64.KoYH, Kim CW, Park CS, Jang HK, Lee SS, Kim SH, classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer. 1998Aug 15;83(4):806-12.
  65. 65.Florentine BD, Staymates B, Rabadi M, Barstis J, Black A. The reliability of fineneedle aspiration biopsy as the initial diagnostic procedure for palpable masses: a 4-year experience of 730 patients from a community hospital-based outpatient aspiration biopsy clinic. Cancer. 2006 Jul 15;107(2):406-16.
  66. 66.Pilozzi E, Pulford K, Jones M: Coexpression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol 1998, 186:140–143.
  67. 67.Picker LJ, Brenner MB, Weiss LM, Smith SD, Warnke RA: Discordant expression of CD3 and T-cell receptor b-chain antigens in T-lineage lymphomas. Am J Pathol 1987, 129:434–440. 21 21 Majmaah Journal of Health Sciences ,Vol. 6, Issue 2, September 2018, Muharam - 1440 Application of Fine NeedleAspiration Biopsy and Immunohistochemical Diagnostic Markers in the Identification of Oral Primary...
  68. 68.Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA: Immunophenotypic criteria for the diagnosis of non-Hodgkin’s lymphoma. Am J Pathol 1987, 128:181–
  69. 69.Weiss LM, Crabtree GS, Rouse RV, Warnke RA: Morphologic and immunologic characterization of 50 peripheral T-cell lymphomas. Am J Pathol 1985, 118:316–324.
  70. 70.Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier- Lacombe MJ:ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998, 91:2076–2084.
  71. 71.Beljaards RC, Kaudewitz P, Berti E, Gianotti R, Neumann C, Rosso R: Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients. Cancer 1993, 71:2097–2104.
  72. 72.Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M: Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995, 86:1954–1960.
  73. 73.Bitter MA, Franklin WA, Larson RA, McKeithan TW, Rubin CM, Le Beau MM: Morphology in Ki-1(CD30)- positive non-Hodgkin’s lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23; q35). Am J Surg Pathol 1990, 14:305–316.
  74. 74.Mason DY, Krissansen GW, Davey FR, Crumpton MJ, Gatter KC: Antisera against epitopes resistant to denaturation on T3 (CD3) antigen can detect reactive and neoplastic T cells in paraffin embedded tissue biopsy specimens. J Clin Pathol 1988, 41:121–127.
  75. 75.Niu H. The proto-oncogene BCL-6 in normal and malignant B cell development. Hematol Oncol.2002;20:155–66.
  76. 76.DentAL,Vasanwala FH,Toney LM. Regulation of gene expression by the protooncogene BCL-6. Crit Rev Oncol Hematol. 2002;41:1–9.
  77. 77.Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med.2004;350:1828–37.
  78. 78.Frei M, Dubach P, Reichart PA, Schmitt AM, Mueller-Garamvölgyi E, Bornstein MM. Diffuse swelling of the buccal mucosa and palate as first and only manifestationofanextranodalnon-Hodgkin‘double-hit’lymphoma: Report of a case. Oral Maxillofac Surg. 2012;16:69–74.
  79. 79.Vose JM. Current approaches to the management of non-Hodgkin’s lymphoma. Semin Oncol.1998;25:483–91.
Majmaah Journal of Health Sciences · eISSN 1658-8223 · Majmaah University · open access